Literature DB >> 3191477

Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.

R K Jain1, L T Baxter.   

Abstract

The therapeutic efficacy of monoclonal antibodies (MAbs), bound to radionuclides, chemotherapeutic agents, toxins, growth factors, or effector antibodies, depends upon their ability to reach their target in vivo in adequate quantities. Despite the high vascular permeability and interstitial transport coefficients in tumor tissue compared to several normal tissues, MAbs and their fragments do not distribute homogeneously in a tumor. Heterogeneity of tumor-associated antigen expression alone cannot explain this maldistribution of MAbs in tumors. We propose that in addition to the heterogeneous blood perfusion, hindered diffusion in the interstitium, and extravascular binding of MAbs, elevated interstitial pressure is responsible for the poor penetration of MAbs into tumors. Elevated interstitial pressure principally reduces the driving force for extravasation of fluid and macromolecules in tumors, and also leads to an experimentally verifiable, radially outward convection which opposes the inward diffusion. We present here mathematical models for transport of fluid and macromolecules in a tumor. To illustrate the significance of elevated interstitial pressure, these models are used to describe the interstitial pressure, interstitial fluid velocity, and concentration of nonbinding macromolecules as a function of radial position in a uniformly perfused tumor. The key result of these models is that the filtration of fluid from blood vessels in a uniformly perfused tumor is (a) spatially heterogeneous, (b) a result of elevated interstitial pressure, and (c) sufficient to explain the heterogeneous distribution of macromolecules in tumors. Nonuniform blood flow, and extravascular binding would enhance this heterogeneity in the solute distribution considerably. The results of the models also agree with the following experimental data: (a) tumor interstitial pressure is low in the periphery and it increases toward the center of the tumor; (b) the radially outward fluid velocity at the tumor periphery predicted by the model is of the same order of magnitude as measured in tissue-isolated tumors; and (c) immediately after bolus injection, the concentration of macromolecules is higher in the periphery than in the center; however, at later time periods the peripheral concentration is lower than in the center. These results have significant implications not only for MAbs and their fragments, but for other biologically useful macromolecules (e.g., cytokines) produced by genetic engineering for cancer diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191477

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  187 in total

1.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 2.  Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.

Authors:  Hemant Sarin
Journal:  Ther Deliv       Date:  2010-08

3.  Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.

Authors:  P Vajkoczy; M D Menger; B Vollmar; L Schilling; P Schmiedek; K P Hirth; A Ullrich; T A Fong
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

4.  Interstitial fluid pressure correlates with intravoxel incoherent motion imaging metrics in a mouse mammary carcinoma model.

Authors:  Sungheon Kim; Lindsey Decarlo; Gene Y Cho; Jens H Jensen; Daniel K Sodickson; Linda Moy; Silvia Formenti; Robert J Schneider; Judith D Goldberg; Eric E Sigmund
Journal:  NMR Biomed       Date:  2011-11-09       Impact factor: 4.044

5.  Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert L Vessella
Journal:  Bioconjug Chem       Date:  2011-05-05       Impact factor: 4.774

6.  Preclinical evaluation of Mab CC188 for ovarian cancer imaging.

Authors:  M Xu; M P Rettig; G Sudlow; B Wang; W J Akers; D Cao; D G Mutch; J F DiPersio; S Achilefu
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

7.  Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors.

Authors:  Shutao Wang; In Soo Shin; Hilary Hancock; Beom-su Jang; Hyung-sub Kim; Sang Myung Lee; Vesna Zderic; Victor Frenkel; Ira Pastan; Chang H Paik; Matthew R Dreher
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

8.  Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.

Authors:  Ingrid Leguerney; Nathalie Lassau; Serge Koscielny; Mélanie Rodrigues; Christophe Massard; Valérie Rouffiac; Baya Benatsou; Jessie Thalmensi; Olivia Bawa; Paule Opolon; Pierre Peronneau; Alain Roche
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

9.  Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.

Authors:  A Preda; P A Wielopolski; T L M Ten Hagen; M van Vliet; J F Veenland; G Ambagtsheer; S T van Tiel; M W Vogel; A M M Eggermont; G P Krestin; C F van Dijke
Journal:  MAGMA       Date:  2004-10-10       Impact factor: 2.310

10.  Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging.

Authors:  Kenneth M Tichauer; Sophie J Deharvengt; Kimberley S Samkoe; Jason R Gunn; Marcus W Bosenberg; Mary-Jo Turk; Tayyaba Hasan; Radu V Stan; Brian W Pogue
Journal:  Mol Imaging Biol       Date:  2013-11-12       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.